A reading-room view of the laboratory, regulatory and toxicology records that sit behind the ingredient — kept on a separate page so the product page stays a product page. 一份关于成分背后实验、监管与毒理记录的「阅读室」——独立成页，以确保产品页保持产品页的本分。
The hydrolyzed extract has been characterised in third-party accredited laboratories. The data below describe ingredient-level findings on cellular and biochemical assays. They are research outputs and do not, by themselves, predict in-use cosmetic outcomes. 水解精萃曾在第三方认可实验室完成表征。下列数据为细胞与生化层面的成分级研究结论。其属于研究输出，并不直接预测化妆品的使用体验或疗效。
| Assay检测 | Endpoint指标 | Reported result报告结果 | Type类型 |
|---|---|---|---|
| Sialic acid quantification唾液酸定量 | HPLC, NANA | ≥ standardised batch spec符合标准批次 | QC release质控放行 |
| Glycan ratio糖比 | Sialic / hexose唾液酸/己糖 | 0.5 – 0.9 | Process control工艺控制 |
| Type-I collagen synthesisI 型胶原合成 | Fibroblast culture成纤维细胞培养 | > 20× control (in vitro)> 20×对照（体外） | In vitro体外 |
| Endogenous factor expression内源因子表达 | FGF-7 / HGF / IGF-1 / EGF | > 50% over baseline (in vitro)> 基线 50%（体外） | In vitro体外 |
| Hyaluronic acid synthesis透明质酸合成 | GAG ELISA | Increase reported报告升高 | In vitro体外 |
| Skin sensitisation (HRIPT proxy)皮肤致敏（HRIPT 替代） | Patch panel斑贴测试 | No sensitisation observed未观察到致敏 | Tox毒理 |
"In vitro" denotes assays performed on isolated cells. Cellular outputs do not directly translate to product efficacy on living scalps.「体外」即在离体细胞上完成的实验。细胞结果不能直接换算为成品在活人头皮上的功效。
In China, the formula has been registered with the National Medical Products Administration (NMPA) as a "Special-Purpose Cosmetic" — the regulatory category that, in the Chinese cosmetic framework, applies to products intended to support hair-fall-related cosmetic outcomes. Registration in one jurisdiction does not extend any claim into another. In Singapore the product is sold strictly as a general cosmetic. 在中国，本配方已于国家药品监督管理局（NMPA）注册为「特殊用途化妆品」。该类别在中国监管框架下用于针对掉发相关化妆品诉求的产品。一国注册不构成对他国的功效主张延伸。在新加坡，本品严格作为普通化妆品销售。
A Chinese SPC registration is one external indicator that the formula passed a third-party regulator's review for ingredient safety, manufacturing standard, and category-specific testing in that jurisdiction. It is not a Singapore HSA product license; in Singapore the product is notified as a cosmetic. We surface the record because it is part of the ingredient's research file — not as an SG efficacy claim. 中国「特殊用途化妆品」注册是一项外部信号——表明配方在该司法辖区内通过了第三方监管对成分安全、生产质量与品类检测的审查。它不是新加坡 HSA 的产品许可。在新加坡，本品按化妆品备案。我们公开此记录，因其属于成分研究档案的一部分，并非对新加坡市场的功效主张。
The hydrolysis method underpinning the extract is protected across five jurisdictions. Patents protect the method, not the product's market claim.支撑该精萃的水解工艺在五个司法辖区受到专利保护。专利保护的是方法，不是产品的市场主张。
| Jurisdiction司法辖区 | Number专利号 | Scope范围 |
|---|---|---|
| USA | US 10,610,537 B2 | Hydrolysis method & composition水解工艺与组合物 |
| Japan | JP 6762027 | Hydrolysis method & composition水解工艺与组合物 |
| China | 107778332 | Hydrolysis method & composition水解工艺与组合物 |
| Hong Kong | HK 1245050 | Hydrolysis method & composition水解工艺与组合物 |
| Macau | J/002932 | Hydrolysis method & composition水解工艺与组合物 |
Tests follow conventional cosmetic-ingredient toxicology protocols. Reports archived at the brand R&D office and available to authorised regulators on request.检测遵循通行的化妆品成分毒理协议。报告归档于品牌研发办公室，授权监管机构可申请查阅。
| Study研究 | Type类型 | Reported endpoint*报告指标* | Compliant SG framingSG 合规表述 |
|---|---|---|---|
| 12-week clinical test12 周临床测试 | Lab-conducted (中检科健 GT00172024565130)实验室检测（中检科健 GT00172024565130） | Local hair density +2.48 hairs/cm² (appearance metric); Sinclair-style visual score median 3 → 4局部毛发密度 +2.48 根/cm²（外观指标）；Sinclair 整体视觉评分中位数 3 → 4 | "Clinically tested to improve the appearance of hair density"「经临床测试，改善毛发密度的外观」 |
| DV reader trialDV 读者实测 | Third-party reader perception study (10 readers, 45 days)第三方读者主观研究（10 人 45 天） | 9/10 noticed baby hairs; 4.1⭐ average9/10 看到细绒毛；4.1⭐ 平均 | "Self-assessed by trial participants. Individual results may vary."「受试者自评，实际效果因人而异。」 |
"Clinically tested" — not "clinically proven". SG cosmetic compliance language uses "tested" to describe that a study was conducted; "proven" implies a therapeutic effect that a cosmetic may not claim. The DV reader trial is a perception study, not an interventional clinical trial, and is always cited with the "self-assessed" disclaimer. 「经临床测试」而非「临床证实」。新加坡化妆品合规用语使用「测试」表示研究曾进行；「证实」暗示治疗效果——化妆品不得作此主张。DV 读者评测是主观研究，不是干预性临床试验，引用时永远附带「受试者自评」声明。
* Per HSA / SCAP / ASAS compliance, all numerical claims that describe an outcome are presented as descriptions of the appearance of hair density, scalp condition, or self-assessed reader experience — not as therapeutic outcomes.* 依 HSA / SCAP / ASAS 法规，所有数值描述均被表述为：毛发密度的外观、头皮状态或读者自评体验，并非治疗结果。
In China, several public hospitals have conducted real-world observational studies (RWS) on the cosmetic application of the extract — observing how users describe their experience over weeks of use. RWS records appearance, comfort, and self-reported satisfaction; they are not interventional clinical trials. 在中国，多家公立医院开展了该精萃化妆品级使用的真实世界观察（RWS）——记录使用者数周内的体验描述。RWS 记录的是外观、舒适度与自我报告的满意度，并非干预性临床试验。
Observational records collected outside Singapore describe ingredient/formulation behaviour in those local markets. They do not transfer to the MYSAO product as sold in Singapore, where the product is positioned, presented and notified as a general cosmetic. 在新加坡境外采集的观察性记录，描述的是该成分/配方在当地市场的表现，不等同于新加坡销售的 MYSAO 产品。在新加坡，本品按普通化妆品定位、表述与备案。
SCAP / ASAS · Mandatory Notice: There is no scientific proof that any product (except certain registered medicinal products) or service can retard hair loss or promote hair growth. Individual results may vary. SCAP / ASAS · 法定声明：没有科学证明任何产品（某些注册药品除外）或服务可以延缓脱发或促进毛发生长。实际效果因人而异。